Hennion & Walsh Asset Management Inc. Trims Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA

Hennion & Walsh Asset Management Inc. lessened its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 35.0% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 79,200 shares of the company’s stock after selling 42,619 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.10% of Kiniksa Pharmaceuticals International worth $3,267,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Rubric Capital Management LP grew its position in Kiniksa Pharmaceuticals International by 2.3% during the third quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock valued at $155,320,000 after buying an additional 90,194 shares during the period. Arrowstreet Capital Limited Partnership raised its position in Kiniksa Pharmaceuticals International by 45.3% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock worth $41,481,000 after acquiring an additional 332,846 shares during the period. Qube Research & Technologies Ltd boosted its stake in shares of Kiniksa Pharmaceuticals International by 277.8% during the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after acquiring an additional 653,236 shares during the last quarter. Millennium Management LLC grew its position in shares of Kiniksa Pharmaceuticals International by 8.7% during the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after acquiring an additional 67,452 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Kiniksa Pharmaceuticals International by 16.3% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 725,355 shares of the company’s stock valued at $28,166,000 after acquiring an additional 101,666 shares during the period. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Analyst Upgrades and Downgrades

KNSA has been the subject of several analyst reports. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. Wells Fargo & Company boosted their price target on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Wedbush upped their price target on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Canaccord Genuity Group assumed coverage on Kiniksa Pharmaceuticals International in a research note on Thursday, February 19th. They issued a “buy” rating and a $62.00 price objective on the stock. Finally, Zacks Research raised Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Kiniksa Pharmaceuticals International has a consensus rating of “Moderate Buy” and an average target price of $55.29.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA stock opened at $48.15 on Wednesday. Kiniksa Pharmaceuticals International, plc has a one year low of $18.25 and a one year high of $49.12. The company’s fifty day moving average price is $45.15 and its 200-day moving average price is $41.67. The company has a market capitalization of $3.69 billion, a price-to-earnings ratio of 65.07 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The firm had revenue of $202.13 million during the quarter, compared to the consensus estimate of $200.86 million. During the same period in the prior year, the company posted ($0.12) EPS. The company’s quarterly revenue was up 65.0% on a year-over-year basis. Equities research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Barry D. Quart sold 12,528 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $45.27, for a total value of $567,142.56. Following the transaction, the director directly owned 12,546 shares of the company’s stock, valued at approximately $567,957.42. The trade was a 49.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Mark Ragosa sold 17,845 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $43.28, for a total value of $772,331.60. Following the completion of the transaction, the chief financial officer directly owned 12,086 shares in the company, valued at approximately $523,082.08. This represents a 59.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 48,605 shares of company stock worth $2,122,646 over the last 90 days. Company insiders own 53.48% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.